Asia Genomics will make CellMax's tests, including the CellMax-DNA Genetic Cancer Risk Test Assure and the CellMax-CRC Protect Test, available immediately.
The assay employs nanoplasmonics and protein-signal multiplexing in taking aim at early clinical detection of pancreatic ductal adenocarcinoma.
The test on the Alinity platform is for use in the POC or clinical laboratory setting, and for the quantitative measurement of glucose in arterial and venous whole blood.
The collaboration will leverage the firms' technologies to identify patients most likely to develop pancreatic cancer and to detect the cancer in the earliest stage.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
In support of the launch, researchers published a study demonstrating the test can help improve diagnosis of patients with unclear results from standard cytology methods.
The results indicate that while blood-based assays can be useful, tissue biopsies should remain the gold standard when available, said one of the study authors.
The study, called Panfam-1, will analyze 1,000 individuals at high risk of familial pancreatic cancer over three years using the company's antibody array test.